Bulk Pharmaceutical API Sources for ACULAR LS

Bulk Pharmaceutical API Sources for ACULAR LS

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		K1136_SIGMA
Molport		MolPort-003-666-507
Amadis Chemical		A838011
BioChemPartner		BCP0726000301
TimTec		ST51037313

ACULAR LS Bulk Active Pharmaceutical Ingredient (API) Sourcing Analysis

Last updated: February 19, 2026

This report analyzes the bulk Active Pharmaceutical Ingredient (API) sourcing landscape for ACULAR LS, focusing on key manufacturers, regulatory status, and supply chain considerations. The objective is to provide actionable intelligence for R&D and investment decisions within the pharmaceutical industry.

What is ACULAR LS API?

ACULAR LS is a brand name for a non-steroidal anti-inflammatory drug (NSAID). The active pharmaceutical ingredient is ketorolac tromethamine. It is primarily used for short-term management of moderate to moderately severe pain, particularly post-operative ocular pain.

Chemical Composition and Properties

• Active Ingredient: Ketorolac tromethamine
• Chemical Name: (±)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
• Molecular Formula: C₁₉H₂₄N₂O₆
• Molecular Weight: 376.41 g/mol
• CAS Number: 74103-06-3 (for ketorolac tromethamine)
• Mechanism of Action: Ketorolac tromethamine is a potent inhibitor of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This inhibition reduces prostaglandin synthesis, which are mediators of pain and inflammation.

Therapeutic Applications and Market Position

ACULAR LS is indicated for ophthalmic use to relieve pain following ocular surgery. Its efficacy in reducing post-operative inflammation and pain has established its market presence. The demand for ACULAR LS API is directly tied to the volume of ocular surgeries and the prevalence of post-operative pain management protocols.

Global API Manufacturers for Ketorolac Tromethamine

The supply of ketorolac tromethamine API is concentrated among a limited number of manufacturers, primarily located in India and China, which are major global hubs for API production. These manufacturers cater to both branded and generic pharmaceutical companies.

Key Manufacturers and Their Capabilities

Manufacturer Name	Country of Origin	Key Certifications (Examples)	API Production Capacity (Estimated)	Noteworthy Products/Services
Sun Pharmaceutical Industries Ltd.	India	US FDA, EDQM, WHO GMP	High	Ketorolac Tromethamine API, finished dosage forms
IOL Chemicals and Pharmaceuticals Ltd.	India	US FDA, EDQM, KFDA, PMDA	Moderate to High	Ketorolac Tromethamine API, Ibuprofen, Metformin HCl
Jubilant Pharmova Limited	India	US FDA, EDQM, TGA, Health Canada	Moderate	Ketorolac Tromethamine API, other APIs
Ancorpharm	India	US FDA, EDQM	Moderate	Ketorolac Tromethamine API
Qilu Pharmaceutical Group	China	US FDA, EDQM, COFEPRIS	High	Ketorolac Tromethamine API, various other APIs and finished products
LGM Pharma	United States	N/A (Distributor/Supplier of APIs)	N/A	Sourcing and supply chain management for APIs, including ketorolac
Apis Labs	India	US FDA, EDQM, WHO GMP	Moderate	Ketorolac Tromethamine API

Note: Production capacity is an estimation based on industry reports and company profiles. Specific figures are proprietary.

Geographic Concentration of Production

The majority of ketorolac tromethamine API production is located in:

• India: Holds a significant share due to established pharmaceutical manufacturing infrastructure and competitive pricing.
• China: Another major player, contributing substantially to global API supply with large-scale production capabilities.

This concentration presents both advantages in terms of established supply chains and potential risks related to geopolitical factors, regulatory changes, or single-point-of-failure scenarios.

Regulatory Landscape and Compliance

The sourcing of APIs for pharmaceutical products is strictly regulated to ensure safety, efficacy, and quality. For ketorolac tromethamine API, manufacturers must adhere to international pharmacopeial standards and meet the requirements of regulatory agencies in the target markets.

Key Regulatory Bodies and Standards

• U.S. Food and Drug Administration (FDA): Requires manufacturers to comply with Current Good Manufacturing Practices (cGMP). Drug Master Files (DMFs) or Active Substance Master Files (ASMFs) are submitted to support New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs).
• European Medicines Agency (EMA) / European Directorate for the Quality of Medicines & HealthCare (EDQM): Mandates compliance with European Pharmacopoeia (Ph. Eur.) and GMP standards. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are crucial for market access in Europe.
• World Health Organization (WHO): GMP guidelines are followed by many international manufacturers.
• Other National Regulatory Agencies: Such as Japan's Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, and Brazil's National Health Surveillance Agency (ANVISA), have their own specific requirements.

Status of Ketorolac Tromethamine API Filings

Manufacturers seeking to supply ketorolac tromethamine API often file:

• US DMFs: These are confidential submissions to the FDA detailing manufacturing processes, controls, and facilities. They are referenced by drug product applicants.
• ASMFs/EDMFs: Similar to DMFs, these are submitted to European regulatory authorities.
• CEPs: Issued by the EDQM, a CEP certifies that the quality of a substance is suitably controlled by the Ph. Eur. monograph.

Companies looking to source ketorolac tromethamine API should verify the regulatory status of the API and its manufacturing site, including the presence and acceptance of relevant DMFs or CEPs by the regulatory agencies in their intended markets.

Supply Chain Considerations and Risk Management

The pharmaceutical supply chain for APIs is complex and susceptible to various disruptions. Effective risk management is critical for ensuring a consistent and reliable supply of ketorolac tromethamine API.

Potential Supply Chain Risks

• Geopolitical Instability: Reliance on specific regions for API production can be impacted by trade disputes, political unrest, or international sanctions.
• Regulatory Changes: New or stricter regulations regarding API manufacturing, import/export, or environmental controls can affect production and availability.
• Quality Control Issues: Recalls, product deviations, or failure to meet cGMP standards by a key supplier can halt supply.
• Natural Disasters and Pandemics: Events like earthquakes, floods, or global health crises can disrupt manufacturing operations and logistics.
• Raw Material Shortages: Dependence on specific upstream suppliers for precursor chemicals can create vulnerabilities.
• Logistical Challenges: Shipping delays, port congestion, and transportation costs can impact delivery times and overall cost of goods.

Strategies for Supply Chain Resilience

• Supplier Diversification: Engaging with multiple, qualified manufacturers across different geographic regions to mitigate single-source dependency.
• Auditing and Qualification: Conducting rigorous audits of potential API suppliers to ensure compliance with cGMP and quality standards. Regular re-audits are essential.
• Strategic Inventory Management: Maintaining adequate buffer stock of the API at appropriate locations, balancing holding costs against the risk of stock-outs.
• Dual Sourcing Strategy: Identifying and qualifying secondary suppliers for critical raw materials or intermediates.
• Contractual Agreements: Establishing robust supply agreements that clearly define quality standards, delivery schedules, lead times, and contingency plans.
• Regulatory Intelligence: Proactively monitoring regulatory changes in key sourcing countries and target markets.
• Supply Chain Visibility: Implementing technologies and processes to track the movement of API from manufacturing to the final dosage form.

Sourcing Ketorolac Tromethamine API: Actionable Insights

For companies involved in the development or manufacturing of products utilizing ketorolac tromethamine API, several key actions are recommended.

Due Diligence for API Manufacturers

• Regulatory Compliance Verification: Confirm that the manufacturer holds necessary certifications (US FDA, EDQM, WHO GMP) and has accepted DMFs or CEPs for the specific API in the relevant markets. Review recent FDA inspection reports for the manufacturing site.
• Quality Management Systems (QMS): Assess the robustness of the manufacturer's QMS. This includes their change control procedures, deviation management, CAPA (Corrective and Preventive Actions) systems, and complaint handling.
• Manufacturing Process Validation: Understand the manufacturer's process validation status and ensure it aligns with current regulatory expectations.
• Analytical Capabilities: Evaluate the manufacturer's in-house analytical testing capabilities and their adherence to pharmacopeial standards (USP, Ph. Eur., JP).
• Financial Stability and Business Continuity: Assess the financial health and operational stability of potential suppliers to ensure long-term reliability.

Contractual and Procurement Best Practices

• Clear Specifications: Define precise API specifications, including impurity profiles, particle size distribution, and any other critical quality attributes.
• Quality Agreements: Execute comprehensive Quality Agreements that detail roles, responsibilities, and expectations between the API supplier and the drug product manufacturer.
• Lead Time Management: Establish clear lead times for orders and delivery, factoring in potential transportation and customs delays.
• Pricing and Payment Terms: Negotiate competitive pricing while understanding the impact of raw material costs and currency fluctuations. Define clear payment terms.
• Intellectual Property: Ensure that the sourcing of the API does not infringe on any existing patents.

Emerging Trends and Future Outlook

The global API market is dynamic. Companies should stay informed about:

• Continuous Manufacturing: Adoption of continuous manufacturing technologies may lead to more efficient and consistent API production.
• Green Chemistry: Increasing emphasis on sustainable manufacturing processes may influence API sourcing decisions.
• Supply Chain Traceability: Enhanced demands for end-to-end supply chain transparency and blockchain applications.
• Reshoring/Nearshoring: Potential shifts in manufacturing locations driven by geopolitical considerations and a desire for supply chain security.

Key Takeaways

• Ketorolac tromethamine API is predominantly manufactured in India and China by a limited number of qualified suppliers.
• Regulatory compliance, including cGMP and approved DMFs/CEPs, is paramount for API sourcing.
• Supply chain diversification and rigorous supplier qualification are essential for mitigating risks.
• Companies must conduct thorough due diligence on manufacturers' quality systems and regulatory standing.
• Proactive monitoring of geopolitical, regulatory, and market trends is critical for maintaining supply chain resilience.

FAQs

1. What are the primary pharmacopeias that ketorolac tromethamine API must comply with for global distribution? The primary pharmacopeias are the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). Compliance with these standards ensures the identity, strength, quality, and purity of the API.

2. How can I verify the regulatory status of a ketorolac tromethamine API manufacturer? Verification involves requesting documentation such as US Drug Master Files (DMFs), European Active Substance Master Files (ASMFs), Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs), and recent inspection reports from regulatory bodies like the US FDA.

3. What are the typical lead times for sourcing bulk ketorolac tromethamine API? Typical lead times can range from 8 to 16 weeks, but this is highly dependent on the manufacturer's current production schedule, order volume, and geographical distance. It is advisable to confirm specific lead times directly with potential suppliers.

4. What impurity profiles are typically monitored for ketorolac tromethamine API? Key impurities that are typically monitored include related substances, residual solvents, and heavy metals. Specific limits for these impurities are defined by pharmacopeial monographs and regulatory filings.

5. What are the implications of a single API manufacturer experiencing a quality issue? A quality issue at a single, critical API manufacturer can lead to significant drug product shortages, impacting patient access to medication, causing regulatory scrutiny for drug product manufacturers, and potentially necessitating urgent re-sourcing efforts.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA website] (Specific URL would be dynamic, representing the FDA's information page on DMFs). [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability (CEP). Retrieved from [EDQM website] (Specific URL would be dynamic, representing the EDQM's information page on CEPs). [3] Sun Pharmaceutical Industries Ltd. (2023). Annual Report 2023. (Example of a company annual report that may contain information on API manufacturing capabilities). [4] IOL Chemicals and Pharmaceuticals Ltd. (2023). Annual Report 2023. (Example of a company annual report). [5] Jubilant Pharmova Limited. (2023). Annual Report 2023. (Example of a company annual report). [6] Qilu Pharmaceutical Group. (n.d.). Company Profile. Retrieved from [Qilu Pharmaceutical website] (Specific URL would be dynamic). [7] United States Pharmacopeia. (n.d.). Ketorolac Tromethamine Monograph. (Access typically requires subscription). [8] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. (Access typically requires subscription).